Arn 509

Manufactured by Selleck Chemicals

ARN-509 is a selective androgen receptor modulator (SARM) used for research purposes. It is a non-steroidal compound that binds to the androgen receptor and exhibits tissue-selective anabolic and androgenic effects. The core function of ARN-509 is to act as a research tool to study the pharmacological properties and potential therapeutic applications of selective androgen receptor modulators.

Automatically generated - may contain errors

Lab products found in correlation

Nutlin 3, by Selleck Chemicals (1 mentions) R1881, by Selleck Chemicals (1 mentions) Dihydrotestosterone dht, by Selleck Chemicals (1 mentions) Mg132, by Selleck Chemicals (1 mentions) Mdv3100, by Selleck Chemicals (1 mentions) Bicalutamide, by Bio-Techne (1 mentions)

2 protocols using arn 509

Prostate Cancer Cell Culture and Inhibitor Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

LNCaP, PC3 and 22RV1 cells (Chinese Academy of Sciences) were cultured using RPMI1640 containing 10% serum. Myc-CaP cells were obtained from Shanghai Jiao Tong University (Shanghai, China). HEK293T was provided by the Stem Cell Bank and cultured using DMEM containing 10% serum. Androgen deprivation was conducted by culturing cells in RPMI1640 (5% charcoal-stripped serum) for 48 h.
ENZ (Cat# HY-70002), actinomycin D (ACTD) (Cat# HY-17559) and cycloheximide (CHX Cat# 66-81-9) were purchased from MCE. ARN-509 (Cat# 956104-40-8), ODM-201 (Cat# 1297538-32-9), MG132 (Cat# 1211877-36-9), dihydrotestosterone (DHT, Cat# 521-18-6), Nutlin3 (Cat# 890090-75-2) and R1881(Cat# 965-93-5) were obtained from Selleck. Recombinant Human MDM2/HDM2 Protein was obtained from R&D.

Li Y., Chu Y., Shi G., Wang X., Ye W., Shan C., Wang D., Zhang D., He W., Jiang J., Ma S., Han Y., Zhao Z., Du S., Chen Z., Li Z., Yang Y., Wang C., Xu X, & Wu H. (2022). A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica. B, 12(11), 4165-4179.

+ Open protocol

+ Expand

Inhibition of Androgen Receptor Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bicalutamide (Tocris, cat.#3389), ARN-509 (Selleck Chemicals, cat.#S2840), MDV3100 (Selleck Chemicals, cat.#S1250), DHT (Wako, cat.#045-26071). ONC1-13B was synthesized at Chemical Diversity Research Institute. Stock and serial dilutions were in dimethylsulfoxide (DMSO) unless otherwise specified.

Ivachtchenko A.V., Mitkin O.D., Kudan E.V., Rjahovsky A.A., Vorobiev A.A., Trifelenkov A.S., Shevkun N.A., Proskurina O.V., Kravchenko D.V, & Karapetian R.N. (2014). Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. Journal of Cancer, 5(2), 133-142.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!